The US Food and Drug Administration (FDA) has approved Desmoda (desmopressin acetate) oral solution for the management of arginine vasopressin deficiency (AVP-D).
AVP-D is a rare neuroendocrine disorder caused by the loss or impaired function of vasopressinergic neurons in the hypothalamus and posterior pituitary gland. This results in impaired synthesis and secretion of AVP. A deficiency of AVP causes the inability to concentrate urine and excessive renal water loss, leading to hypotonic polyuria. The primary symptoms of AVP-D are polydipsia, polyuria, and nocturia. Additional symptoms may include weakness, lethargy, fatigue, and myalgias. AVP-D has previously been called central diabetes insipidus (CDI). The disease is also known as central diabetes insipidus with an estimated 13,000 people in the US afflicted with this rare condition.
Desmopressin acetate is a synthetic analogue of arginine vasopressin, and Desmoda is the first and only FDA-approved oral liquid formulation. This allows support for precise, individualized dosing due to the disease’s need for careful titration to maintain water balance.
For more information, click here.
To learn more about AVP-D and other rare endocrine disorders, visit https://checkrare.com/diseases/endocrine-disorders/
